Jack Merrit Gwaltney

Author:

Jack M. Gwaltney

ISBN #:

0471015989

US Patent:

54220971, Jun 6, 1995

Filed:

Aug 26, 1993

Appl. No.:

8/112588

Inventors:

Jack M. Gwaltney - Free Union VA

Assignee:

University of Virginia - Charlottesville VA
Center for Innovative Technology - Herndon VA

International Classification:

A01N 2534
A61K 914
A61K 948
A61L 904

US Classification:

424 45

Abstract:

The common cold is best treated by providing a combination of antiviral agents and antiinflammatory compounds to a patient infected with a cold virus. An antiviral agent and two antiinflammatory compounds given to a person infected with a cold virus simultaneously reduces the likelihood of a cold developing and the amount and duration of viral shedding, as well as substantially reduces the severity of individual cold symptoms and the overall number and severity of cold symptoms. Supplementing the activity of the combined antiviral and antiinflammatory agents with such compounds as antihistamines and alpha agonists results in suprisingly good nasal benefits. The combination therapy, termed COVAM therapy, is well tolerated and has no evidence of short-term toxicity.

US Patent:

54926890, Feb 20, 1996

Filed:

Aug 9, 1994

Appl. No.:

8/288214

Inventors:

Jack M. Gwaltney - Free Union VA

Assignee:

The Center for Innovative Technology - Herndon VA
The University of Virginia - Charlottesville VA

International Classification:

A61K 914
A61K 948
A61L 904
A01N 2534

US Classification:

424 45

Abstract:

The common cold and related disorders such as influenza, acute sinusitis, acute otitis, and infectious exacerbations of obstructive pulmonary disease, are best treated by providing a combination of antiviral agents and antiinflammatory compounds to a patient infected with a cold or influenza virus. An antiviral agent and two antiinflammatory compounds given to a person infected with a cold virus simultaneously reduces the likelihood of a cold developing and the amount and duration of viral shedding, as well as substantially reduces the severity of individual cold symptoms and the overall number and severity of cold symptoms. Supplementing the activity of the combined antiviral and antiinflammatory agents with such compounds as antihistamines and alpha agonists results in suprisingly good nasal benefits. Particularly good treatment results when an antiinflammatory compound which will reduce the volume of mucus secretion and/or reduce the viscosity of mucus present in the sinus cavity. The combination therapy, termed COVAM therapy, is well tolerated and has no evidence of short-term toxicity.

US Patent:

60341335, Mar 7, 2000

Filed:

Nov 5, 1993

Appl. No.:

8/147742

Inventors:

J. Owen Hendley - Charlottesville VA
Jack M. Gwaltney - Charlottesville VA
Deborah F. Thacker - Charlottesville VA

Assignee:

The University of Virginia Patents Foundation - Charlottesville VA

International Classification:

A01N 3700
A01N 3100

US Classification:

514573

Abstract:

Frequent application of a virucidal hand lotion containing malic acid, citric acid, and a C. sub. 1-6 alcohol will prevent the hand-to-hand transmission of rhinoviruses and reduce the incidence of the "common cold" caused by rhinoviruses.